alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach
- PMID: 20522009
- DOI: 10.2174/187152710791556177
alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach
Abstract
The classical animal models of Parkinson's disease (PD) rely on the use of neurotoxins, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine and, more recently, the agricultural chemicals paraquat and rotenone, to deplete dopamine (DA). These neurotoxins elicit motor deficits in different animal species although MPTP fails to induce a significant dopaminergic neurodegeneration in rats. In the attempt to better reproduce the key features of PD, in particular the progressive nature of neurodegeneration, alternative PD models have been developed, based on the genetic and neuropathological links between -synuclein ( -syn) and PD. In vivo microdialysis was used to investigate extracellular striatal DA dynamics in MPTP- and -syn-generated rodent models of PD. Acute and sub-acute MPTP intoxication of mice both induce prolonged release of striatal DA. Such DA release may be considered the first step in MPTP-induced striatal DA depletion and nigral neuron death, mainly through reactive oxygen species generation. Although MPTP induces DA reduction, neurochemical and motor recovery starts immediately after the end of treatment, suggesting that compensatory mechanisms are activated. Thus, the MPTP mouse model of PD may be unsuitable for closely reproducing the features of the human disease and predicting potential long-term therapeutic effects, in terms of both striatal extracellular DA and behavioral outcome. In contrast, the -syn-generated rat model of PD does not suffer from a massive release of striatal DA during induction of the nigral lesion, but rather is characterized by a prolonged reduction in baseline DA and nicotine-induced increases in dialysate DA levels. These results are suggestive of a stable nigrostriatal lesion with a lack of dopaminergic neurochemical recovery. The -syn rat model thus reproduces the initial stage and slow development of PD, with a time-dependent impairment in motor function. This article will describe the above experimental PD models and demonstrate the utility of microdialysis for their characterization.
Similar articles
-
Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.Neurotoxicology. 2021 May;84:41-52. doi: 10.1016/j.neuro.2021.02.001. Epub 2021 Feb 4. Neurotoxicology. 2021. PMID: 33549656
-
Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.Neurotoxicology. 2004 Sep;25(5):761-9. doi: 10.1016/j.neuro.2004.05.002. Neurotoxicology. 2004. PMID: 15288507
-
Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.Front Biosci. 2003 Sep 1;8:a155-66. doi: 10.2741/1104. Front Biosci. 2003. PMID: 12957824
-
The MPTP mouse model: cues on DA release and neural stem cell restorative role.Parkinsonism Relat Disord. 2008;14 Suppl 2:S189-93. doi: 10.1016/j.parkreldis.2008.04.029. Epub 2008 Jun 24. Parkinsonism Relat Disord. 2008. PMID: 18579428 Review.
-
The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.Curr Pharm Des. 2011;17(5):489-507. doi: 10.2174/138161211795164095. Curr Pharm Des. 2011. PMID: 21375482 Review.
Cited by
-
Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease.Mol Neurobiol. 2018 Jan;55(1):359-369. doi: 10.1007/s12035-017-0747-4. Mol Neurobiol. 2018. PMID: 28875428
-
Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.Hum Mol Genet. 2013 Aug 15;22(16):3315-28. doi: 10.1093/hmg/ddt192. Epub 2013 May 10. Hum Mol Genet. 2013. PMID: 23666528 Free PMC article.
-
Targeting nicotinic receptors for Parkinson's disease therapy.CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):651-8. doi: 10.2174/187152711797247849. CNS Neurol Disord Drug Targets. 2011. PMID: 21838678 Free PMC article. Review.
-
Neurological morphofunctional differentiation induced by REAC technology in PC12. A neuro protective model for Parkinson's disease.Sci Rep. 2015 May 15;5:10439. doi: 10.1038/srep10439. Sci Rep. 2015. PMID: 25976344 Free PMC article.
-
Neurons and Glia Interplay in α-Synucleinopathies.Int J Mol Sci. 2021 May 8;22(9):4994. doi: 10.3390/ijms22094994. Int J Mol Sci. 2021. PMID: 34066733 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous